Keeping Pace with the Latest Updates in IgAN Disease and Treatments
Released On
September 8, 2025
Expires On
June 30, 2026
Media Type
Internet
Completion Time
30 minutes
Specialty
Nephrology
Topics
IgAN
This program has been funded by an unrestricted educational grant from Calliditas.
Credit Available
- Physicians - maximum of 0.5 AMA PRA Category 1 Credits™
All other healthcare professionals completing this course will be issued a statement of participation.
Target Audience
This activity is designed to meet the educational needs of US-based academic and community nephrologists and other healthcare professionals involved in the management of IgA nephropathy (IgAN).
Program Overview
Episode 1: Assessing the Field: Understanding the Burden of IgAN
Jonathan Barratt & Dana Rizk
Duration: 18:38 minutes
- Signs and symptoms of IgAN
- Epidemiologic burden of IgAN
- Genetic predisposition to IgAN
- Diagnosis and referral pathways for IgAN
- Impact of IgAN on morbidity and mortality
- Impact of IgAN on patients’ quality of life
Episode 2: Understanding the Challenge: Immune Mechanisms Underlying IgAN
Jonathan Barratt & Dawn Caster
Duration: 17 minutes
- Impact of increased lymphoid maturation of B cells on production of IgA
- Antibody response to the increase in galactose deficient (Gd)-IgA and initiation of the ‘4-hit’ mechanism
- Changes in inflammatory cytokines and complement activation leading to glomerular and interstitial fibrosis
- Therapeutic targets currently under investigation for IgAN based on interactions with the immune pathogenesis of disease
Learning Objectives
Upon completion of this educational activity, participants should be better able to:
- Recognize the signs and symptoms of IgAN and patients at risk of disease and disease progression
- Understand how proteinuria and estimated glomerular filtration rate (eGFR) assessments can be used to identify patients at risk of IgAN and requiring referral for biopsy in order to confirm the diagnosis
- Describe the immune processes underlying development and progression of IgAN
- Discuss targets for disease-modifying therapy based on the mechanisms underlying IgAN
Faculty
Jonathan Barratt, MD
Professor of Renal Medicine
University of Leicester, UK
Dana V. Rizk, MD
Professor of Medicine, Division of Nephrology
University of Alabama at Birmingham, USA
Dawn J. Caster, MD
Associate Professor of Medicine, Division of Nephrology
University of Louisville School of Medicine, USA
Accreditation Statement
Partners for Advancing Clinical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation
Physician Continuing Medical Education
Partners designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit™ per episode. Physicians should claim only the credit commensurate with the extent of their participation.
Disclosures of Conflicts Of Interest
Jonathan Barratt
Received consultancy fees for providing speaker service to Alexion Pharmaceuticals, Alnylam Pharmaceuticals, Argenx SE, Astellas Pharma, BioCryst Pharmaceuticals, Calliditas, Chinook Therapeutics, Dimerix, Galapagos NV, Novartis, Omeros Corporation, Travere Therapeutics, Vera Therapeutics, and Visterra.
Received research grants from Argenx SE, Calliditas, Chinook Therapeutics, Galapagos NV, GlaxoSmithKline (GSK plc), Novartis, Omeros Corporation, Travere Therapeutics, and Visterra.
Dana V. Rizk
Received consultancy fees for providing speaker services to BioCryst Pharmaceuticals, Biogen (HiBio), Calliditas Therapeutics (Pharmalink), Chugai Pharmaceutical Co, F. Hoffmann-La Roche, George Clinical, Novartis Pharmaceuticals (formerly Chinook Pharmaceuticals), Otsuka Pharmaceuticals (Visterra), Timberlyne Therapeutics, and Vera Therapeutics.
Received research grants from Calliditas Therapeutics (Pharmalink), F. Hoffmann-La Roche, Novartis Pharmaceuticals (formerly Chinook Pharmaceuticals), Otsuka Pharmaceuticals (Visterra), Travere Therapeutics (Retrophin), Vera Therapeutics, and Vertex Pharmaceuticals.
Is the owner of Reliant Glycosciences LLC
Dawn J. Caster
Received consultancy, speaker, and advisory fees from Alexion PharmaceuticalsAstraZeneca, Aurinia Pharmaceuticals, Cabaletta Bio, Calliditas Therapeutics, Chinook Therapeutics / Novartis, Genentech (Roche Group), GlaxoSmithKline (GSK plc), and Travere Therapeutics.
Instructions for Participation and Credit
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:
- Read the CME/CE information and faculty disclosures.
- Participate in the online activity.
- Submit the evaluation form.
Certificates will be emailed to the participant.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indication(s). The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and further their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Contact Information
For CME questions, contact [email protected].